Effect of extended duration of thromboprophylaxis for medically ill patients

被引:2
|
作者
Wang, Xing [1 ]
Chen, Yuqi [1 ]
Wen, Dingke [1 ]
You, Chao [1 ,2 ]
Ma, Lu [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Neurosurg, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Brain Res Ctr, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China
关键词
Venous thromboembolism; Thromboprophylaxis; Acute disease; Low molecular weight heparin; Direct oral anticoagulant; Stroke; VENOUS THROMBOEMBOLISM; RISK; PROPHYLAXIS; ENOXAPARIN; EVENTS;
D O I
10.1016/j.ejim.2023.03.032
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: There are knowledge gaps regarding the comparative efficacy and safety of various venous thromboprophylaxis regimens with extended timing in patients hospitalized for acute medical illnesses. This study aims to investigate the optimal regimen for the prevention of venous thromboembolism in these patients. Methods: We conducted a Bayesian network meta-analysis of randomized controlled trials (RCTs) comparing different venous thromboprophylaxis regimens for acutely ill medical patients. Outcomes included venous thromboembolism, major bleeding, and all-cause mortality. Risk ratios (RR) and associated 95% credible interval (CrI) were estimated. In addition, we assessed the most effective interventions in a subgroup of patients with stroke. Results: We identified five RCTs involving 40,124 patients. Extended thromboprophylaxis with direct oral anticoagulant (DOAC) (RR 0.78, 95% CrI 0.68 to 0.89) and low molecular weight heparin (LMWH) (RR 0.62, 95% CrI 0.45 to 0.84) were superior to standard therapy in the prevention of venous thromboembolism. However, both of them (DOAC: RR 1.99, 95% CrI 1.38 to 2.92; LMWH: RR 2.56, 95% CrI 1.26 to 5.68) lead to a significant increase in major bleeding). Moreover, both LMWH (RR 0.76, 95% CrI 0.57 to 1.00) and DOAC (RR 0.86, 95% CrI 0.76 to 0.98) with extended thromboprophylaxis showed favorable net clinical benefit compared to standard therapy. Conclusions: Extended thromboprophylaxis, especially with LMWH, showed better efficacy in venous thromboembolism reduction with increased risk of major bleeding. The beneficial effect of LMWH with extended timing has also been shown in stroke patients. Overall, extended thromboprophylaxis is associated with a positive net clinical benefit.
引用
收藏
页码:22 / 30
页数:9
相关论文
共 50 条
  • [31] Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial
    Spyropoulos, Alex C.
    Raskob, Gary E.
    Cohen, Alexander T.
    Ageno, Walter
    Weitz, Jeffrey I.
    Spiro, Theodore E.
    Lu, Wentao
    Lipardi, Concetta
    Barnathan, Elliot S.
    BLOOD, 2019, 134
  • [32] Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis
    Chi, G.
    Nafee, T.
    Korjian, S.
    Daaboul, Y.
    Harrington, R. A.
    Goldhaber, S. Z.
    Hull, R. D.
    Gold, A.
    Cohen, A. T.
    Gibson, C. M.
    EUROPEAN HEART JOURNAL, 2017, 38 : 1204 - 1205
  • [33] Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis
    Chi, G.
    Goldhaber, S. Z.
    Kittelson, J. M.
    Turpie, A. G. G.
    Hernandez, A. F.
    Hull, R. D.
    Gold, A.
    Curnutte, J. T.
    Cohen, A. T.
    Harrington, R. A.
    Gibson, C. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (10) : 1913 - 1922
  • [34] Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients
    Cave, Brandon
    Hough, Augustus
    Dobesh, Paul P.
    PHARMACOTHERAPY, 2018, 38 (06): : 597 - 609
  • [35] Deep vein thromboprophylaxis in medically ill patients: poor compliance and limitations of guidelines
    Muralidhara, K.
    Brock, K.
    Goulden, P.
    Kumar, J.
    CLINICAL MEDICINE, 2007, 7 (06) : 644 - 645
  • [36] The risks and benefits of thromboprophylaxis (TP) among hospitalized medically ill cancer patients
    Carrier, M.
    Wu, C.
    Peterson, E.
    de Wit, C.
    Ma, M.
    Tien, J.
    Polley, G.
    Lee, A. Y.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 208 - 208
  • [37] Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: Methodology for the EXCLAIM study
    Russell D. Hull
    Sebastian M. Schellong
    Victor F. Tapson
    Manuel Monreal
    Meyer-Michel Samama
    Alexander G. G. Turpie
    Peter Wildgoose
    Roger D. Yusen
    Journal of Thrombosis and Thrombolysis, 2006, 22 : 31 - 38
  • [38] Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: Methodology for the EXCLAIM study
    Hull, Russell D.
    Schellong, Sebastian M.
    Tapson, Victor F.
    Monreal, Manuel
    Samama, Meyer-Michel
    Turpie, Alexander G. G.
    Wildgoose, Peter
    Yusen, Roger D.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2006, 22 (01) : 31 - 38
  • [39] The benefit of betrixaban for the extended thromboprophylaxis in acutely ill medical patients
    Scarpa, Daniele
    Denas, Gentian
    Babuin, Luciano
    Pengo, Vittorio
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (03) : 261 - 268
  • [40] Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)
    Gibson, C. Michael
    Chi, Gerald
    Halaby, Rim
    Korjian, Serge
    Daaboul, Yazan
    Jain, Purva
    Arbetter, Douglas
    Goldhaber, Samuel Z.
    Hull, Russel
    Hernandez, Adrian F.
    Gold, Alex
    Bandman, Olga
    Harrington, Robert A.
    Cohen, Alexander T.
    Bello, F.
    Ferrari, A. E.
    Jure, H.
    Macin, S.
    Oliva, M.
    Parody, M.
    Poy, C.
    Baker, R.
    Coughlin, P.
    Finfer, S.
    Rubinfeld, A.
    Huber, K.
    Konig, J.
    Mathies, R.
    Schoenerr, H.
    Adzerikho, I.
    Koryk, V.
    Mikhailova, E.
    Mitkovskaya, N.
    Pimanov, S.
    Polonetsy, L.
    Soroka, N.
    Blockmans, D.
    Delforge, M.
    Dive, A.
    Lienart, F.
    Bizzacchi, J. Annichino
    Fiss, E.
    Freire, A.
    Manenti, E.
    Ramacciotti, E.
    Raymuno, S.
    Rocha, A.
    Dimov, B.
    Grigorov, M.
    Kalpachki, R.
    CIRCULATION, 2017, 135 (07) : 648 - 655